Senores Pharmaceuticals Limited has announced a strategic acquisition that will expand its pharmaceutical manufacturing capabilities. The company's Management Committee of the Board of Directors approved the acquisition of Apnar Pharma Private Limited on December 15, 2025, marking a significant step in the company's growth strategy.

Acquisition Structure and Timeline

Senores Pharmaceuticals has announced the acquisition of a 100% stake in Apnar Pharma Private Limited for a total enterprise value of ₹91.00 crores. The acquisition will be completed in two tranches by Q2 FY2027, with Apnar Pharma becoming a wholly owned subsidiary upon completion.

Financial Structure

The deal structure combines cash payments with debt and liability assumptions, providing a balanced approach to the acquisition financing. The total consideration reflects the strategic value of acquiring established pharmaceutical manufacturing capabilities.

Manufacturing Facility Specifications

The acquired facility in Jambusar, Gujarat represents a state-of-the-art pharmaceutical manufacturing operation that commenced in 2021. The facility received USFDA approval in September 2022 and maintains multiple international regulatory certifications.

Production Capacity and Market Reach

The facility demonstrates significant production capabilities across multiple dosage forms with expansion potential. Current operations serve regulated markets including the US, UK, and Canada.

Target Company Profile

Apnar Pharma Private Limited brings significant manufacturing credentials to the acquisition. The company was incorporated in Gujarat on December 12, 2014, under the Companies Act, 2013, and has established itself as a manufacturer of generic pharmaceutical formulations.

Key operational highlights include:

• USFDA approved manufacturing facility
• UK-MHRA certification
• Health Canada approval
• Manufacturing facility located in Jambusar, Gujarat
• Focus on generic pharmaceutical formulations
• Strong R&D and analytical capabilities

Financial Performance Track Record

Apnar Pharma's revenue performance over the past three years demonstrates the operational scale of the acquisition target.

Strategic Rationale and Synergies

The acquisition provides immediate access to regulated markets including UK and Canada, expanding beyond Senores Pharmaceuticals' current US presence. The deal includes 5 approved ANDAs representing a total market opportunity exceeding $700 million.

According to Swapnil Shah, Promoter Managing Director, the acquisition will enable the company to manufacture select US products from India, improving operational leverage and supporting margin expansion. The facility will strengthen manufacturing capabilities and deepen customer relationships, creating opportunities in the CDMO and CMO segments.

Key strategic benefits include:

• Enhanced market access across regulated territories
• Revenue and cost synergies through cross-selling
• Backward integration via in-house manufacturing
• Improved supply chain control and regulatory compliance
• Expansion of product portfolio and customer penetration

ANDA Portfolio Acquisition

In addition to the facility acquisition, Senores Pharmaceuticals Inc., the company's wholly owned subsidiary, is acquiring a basket of 5 ANDAs from Apnar Pharma's parent company. Of these 5 ANDAs, 3 are validated and qualified, with commercialization expected to begin immediately.

The transaction has been disclosed under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring full compliance with regulatory requirements.

Senores Pharmaceuticals has announced the regulatory approval and commercial launch of Deferiprone Tablets USP in 500mg and 1000mg strengths for the United States market. The pharmaceutical company disclosed this development through a media release filed under Regulation 30 of SEBI listing requirements.

Product Launch and Market Partnership

The newly launched Deferiprone Tablets are bioequivalent and therapeutically equivalent to Ferriprox Tablets manufactured by Chiesi USA, Inc. The product will be marketed and distributed by Dr. Reddy's Laboratories Inc. in the US market, representing a strategic partnership for market penetration.

Market Opportunity and Strategic Focus

According to Symphony data, Deferiprone Tablets in both brand and generic forms generated approximately $70.00 million in US sales for the twelve months ending in recent data. Swapnil Shah, Managing Director of Senores Pharmaceuticals Limited, emphasized the strategic importance of this launch, stating it advances the company's growth through entry into a limited-competition product segment.

The launch aligns with Senores' strategic focus on identifying and entering niche, under-penetrated generic formulations that present opportunities to serve unmet healthcare needs. This approach positions the company in specialized therapeutic areas with reduced competitive pressure.

Company Portfolio and Manufacturing Capabilities

Senores Pharmaceuticals operates as a global, research-driven pharmaceutical company with extensive manufacturing and development capabilities. The company's current portfolio encompasses significant regulatory approvals and pipeline products across multiple markets.

Manufacturing Infrastructure

The company maintains a robust manufacturing infrastructure with facilities strategically located to serve both regulated and emerging markets. Senores operates two formulation manufacturing facilities - one USFDA-approved facility in Atlanta, US, which is DEA and TAABAA compliant for controlled substances, and another WHO-GMP approved facility in Chhatral, Ahmedabad, India.

The company also operates two API manufacturing facilities in India, located in Chhatral and Naroda near Ahmedabad, with regulatory approvals from over 10 countries. Additionally, Senores maintains strong research and development capabilities across three R&D sites to drive its differentiated product portfolio development.